Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents
- 21 October 2002
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (20) , 2893-2897
- https://doi.org/10.1016/s0960-894x(02)00598-x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase ActivityJournal of Medicinal Chemistry, 2001
- CI-1033, a pan-erbB tyrosine kinase inhibitorSeminars in Oncology, 2001
- 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor ActivityJournal of Medicinal Chemistry, 2001
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001
- Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2001
- MEK (MAPKK) inhibitors. Part 2: structure–activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolinesBioorganic & Medicinal Chemistry Letters, 2001
- Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitrilesJournal of Medicinal Chemistry, 2001
- Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapyDrugs of the Future, 2001
- A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine KinaseScience, 1994
- Epidermal growth factor receptor tyrosine kinaseBiochemical Pharmacology, 1994